ImmuCell Files 8-K on Operations & Financial Condition
Ticker: ICCC · Form: 8-K · Filed: Jan 8, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**ImmuCell just dropped an 8-K on its financials, signaling an update on company performance.**
AI Summary
ImmuCell Corporation filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under SEC File Number 001-12934, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health and operational efficiency, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with current information on ImmuCell's financial health, which is crucial for evaluating the company's performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate high-risk events.
Analyst Insight
A smart investor would review the full financial statements and results of operations once they are made available to understand the specific details of ImmuCell's performance and assess any potential impact on the stock.
Key Players & Entities
- ImmuCell Corporation (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- 001-12934 (string) — Commission File Number for ImmuCell Corporation
- ICCC (string) — trading symbol for ImmuCell Corporation
- Nasdaq (string) — exchange where ImmuCell Corporation's common stock is registered
FAQ
What is the purpose of ImmuCell Corporation's 8-K filing dated January 8, 2024?
The 8-K filing by ImmuCell Corporation on January 8, 2024, is intended to report on the company's 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section.
What is the trading symbol and the exchange where ImmuCell Corporation's common stock is registered?
ImmuCell Corporation's common stock trades under the symbol 'ICCC' and is registered on the Nasdaq exchange, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the address and phone number of ImmuCell Corporation's principal executive offices?
The principal executive offices of ImmuCell Corporation are located at 56 Evergreen Drive, Portland, Maine, 04103, and the registrant's telephone number is 207-878-2770, according to the filing.
What is ImmuCell Corporation's state of incorporation and IRS Employer Identification Number?
ImmuCell Corporation is incorporated in 'DE' (Delaware) and its IRS Employer Identification Number is '01-0382980', as detailed in the filing.
Is ImmuCell Corporation considered an emerging growth company according to this 8-K filing?
The filing includes a checkbox section to 'Indicate by check mark whether the registrant is an emerging growth company', but the box is not checked, implying that ImmuCell Corporation does not identify as an emerging growth company under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-01-08 16:05:32
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC Nasdaq I
Filing Documents
- ea191339-8k_immucell.htm (8-K) — 26KB
- ea191339ex99-1_immucell.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-001894.txt ( ) — 224KB
- iccc-20240108.xsd (EX-101.SCH) — 3KB
- iccc-20240108_lab.xml (EX-101.LAB) — 33KB
- iccc-20240108_pre.xml (EX-101.PRE) — 22KB
- ea191339-8k_immucell_htm.xml (XML) — 3KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition On January 8, 2024 ImmuCell Corporation (the Company) issued a press release announcing its unaudited product sales for the year ended December 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated January 8, 2024. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: January 8, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated January 8, 2024. 3